Immunohistochemical analysis of steroid receptors, proliferation markers, apoptosis related molecules, and gelatinases in non-neoplastic and neoplastic endometrium

Annals of Anatomy

Volumn 193, Issue 1, 2011, Pages 43-55

  Amalinei, Cornelia ^a   Cianga, Corina ^a   Balan, Raluca ^a   Cianga, Petru ^a   Giusca, Simona ^a   Caruntu, Irina Draga ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Apoptosis; Endometrial carcinogenesis; Gelatinases; Proliferation; Steroid receptors; TIMP

Indexed keywords

CYCLINE; ESTROGEN RECEPTOR; FAS ANTIGEN; FAS LIGAND; GELATINASE; GELATINASE A; GELATINASE B; PROGESTERONE RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; STEROID RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ANTIBODY LABELING; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

ADULT; CYTOKINES; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GELATINASES; HUMANS; MIDDLE AGED; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 78651439223     PISSN: 09409602     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.aanat.2010.09.009     Document Type: Article

References (59)

1. Abe H., Shibata M.-A., Otsuki Y. Caspase cascade of Fas-mediated apoptosis in human normal endometrium and endometrial carcinoma cells. Mol. Hum. Reprod. 2006, 12:535-541.
2. Atasoy P., Bozdogan O. Molecular markers in endometrial hyperplasia. Gynecol. Oncol. 2006, 11:61-67.
3. Bircan S., Ensari A., Ozturk S. Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and carcinomatous endometrium. Pathol. Oncol. Res. 2005, 11:32-39.
4. Bockman J.V. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 1983, 15:10-17.
5. Boruban M.C., Altundag K., Kilic G.S., Blankstein J. From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures. Eur. J. Cancer Prev. 2008, 17:133-138.
6. Bozdogan O., Atasoy P., Erekul S., Bozdogan N., Bayram M. Apoptosis related proteins and steroid hormone receptors in normal, hyperplastic and neoplastic endometrium. Int. J. Gynecol. Pathol. 2002, 21:375-382.
7. Cao Q.J., Einstein M.H., Anderson P.S., Runowicz C.D., Balan R., Jones J.G. Expression of COX-2, Ki-67, Cyclin D1, and P21 in endometrial endometrioid carcinomas. Int. J. Gynecol. Pathol. 2002, 21:147-154.
8. Chegini N., Rhoton-Vlasak A., Williams R.S. Expression of matrix metalloproteinase-26 and tissue inhibitor of matrix metalloproteinase-3 and -4 in endometrium throughout the normal menstrual cycle and alteration in users of levonorgestrel implants who experience irregular uterine bleeding. Fertil. Steril. 2003, 80:564-570.
9. Cornet P.B., Galant C., Eeckhout Y., Courtoy P.J., Marbaix E., Henriet P. Regulation of matrix metalloproteinase-9/gelatinase B expression and activation by ovarian steroids and LEFTY-A/endometrial bleeding-associated factor in the human endometrium. J. Clin. Endocrinol. Metab. 2005, 90:1001-1011.
10. Curry T.E., Osteen K.G. The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocr. Rev. 2003, 24:428-465.
11. Di Nezza L.A., Misajon A., Zhang J., Jobling T., Quinn M.A., Ostör A.G., Nie G., Lopata A., Salamonsen L.A. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer 2002, 94:1466-1475.
12. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2:161-174.
13. Freitas S., Meduri G., Nestur E., Bausero P., Perrot-Applanat M. Expression of metalloproteinases and their inhibitors in blood vessels in human endometrium. Biol. Reprod. 1999, 61:1070-1082.
14. Galant C., Berliere M., Dubois D., Verougstraele J.C., Charles A., Lemoine P., Kokorine I., Eeckout Y., Courtoy P.J., Marbaix E. Focal expression and final activity of matrix metalloproteinases may explain irregular dysfunctional endometrial bleeding. Am. J. Pathol. 2004, 165:83-94.
15. Giuffre G., Arena F., Scarfi R., Simone A., Todaro P., Tuccari G. Lactoferrin immunoexpression in endometrial carcinomas: relationships with sex steroid hormone receptors (ER and PR), proliferation indices (Ki-67 and AgNOR) and survival. Oncol. Rep. 2006, 16:257-263.
16. Goffin F., Munaut C., Frankenne F., Perrier d'Hauterive S., Beliard A., Fridman V., Nervo P., Colige A., Foidart J.M. Expression pattern of metalloproteinases and tissue inhibitors of matrix metalloproteinases in cycling human endometrium. Biol. Reprod. 2003, 69:976-984.
17. Graesslin O., Cortez A., Fauvet R., Lorenzoto M., Birembaut P., Darai E. Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and-2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study. Ann. Oncol. 2006, 17:637-645.
18. Hale G.E., Hughes C.L., Cline J.M. Endometrial cancer: hormonal factors, the perimenopausal " window of risk" , and isoflavones. J. Clin. Endocrinol. Metab. 2002, 87:3-15.
19. Harada T., Kaponis A., Iwabe T., Taniguchi F., Makrydimas G., Sofikitis N., Paschopoulos M., Paraskevaidis E., Terakawa N. Apoptosis in human endometrium and endometriosis. Hum. Reprod. Update 2004, 10:29-38.
20. Heljasvaara R., Nyberg P., Luostarinen J., Parikka M., Heikkila P., Rehn M., Sorsa T., Salo T., Pihlajaniemi T. Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteinases. Exp. Cell. Res. 2005, 307:292-304.
21. Henriet P., Cornet P.B., Lemoine P., Galant C., Singer C.F., Courtoy P.J., Eeckhout Y., Marbaix E. Circulating ovarian steroids and endometrial matrix metalloproteinases (MMPs). Ann. N. Y. Acad. Sci. 2002, 955:119-138.
22. Hojilla C.V., Mohammed F.F., Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br. J. Cancer 2003, 10:1817-1821.
23. Hu K., Zhong G., He F. Expression of estrogen receptors ERα and ERβ in endometrial hyperplasia and adenocarcinoma. Int. J. Gynecol. Cancer 2005, 15:537-541.
24. Ioachin E. Immunohistochemical tumor markers in endometrial carcinoma. Eur. J. Gynaecol. Oncol. 2005, 26:363-371.
25. Isaka K., Nishi H., Nakada T., Feng Li Y., Ebihara Y., Takayama M. Matrix metalloproteinase-26 is expressed in human endometrium but not in endometrial carcinoma. Cancer 2003, 97:79-89.
26. Ito K., Utsunomiya H., Suzuki T., Saitou S., Akahira J., Okamura K., Yaegashi N., Sasano H. 17beta-Hydroxysteroid dehydrogenases in human endometrium and its disorders. Mol. Cell. Endocrinol. 2006, 248:136-140.
27. Ito K., Utsunomiya H., Yaegashi N., Sasano H. Biological roles of estrogen and progesterone in human endometrial carcinoma-new developments in potential endocrine therapy for endometrial cancer. Endocr. J. 2007, 54:667-679.
28. Jazaeri O., Shupnik M.A., Jazaeri A.A., Rice L.W. Expression of estrogen receptor alpha mRNA and protein variants in human endometrial carcinoma. Gynecol. Oncol. 1999, 74:38-47.
29. Konno R., Yamakawa H., Utsunomiya H., Ito K., Sato S., Yajima A. Expression of survivin and Bcl-2 in the normal human endometrium. Mol. Hum. Reprod. 2000, 6:529-534.
30. Lambert V., Wielockx B., Munaut C., Galopin C., Jost M., Itoh T., Werb Z., Baker A., Libert C., Krell H., Foidart J.M., Noel A., Rakic J.M. MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. FASEB 2003, 17:2290-2292.
31. Lax S.F. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows. Arch. 2004, 444:213-223.
32. Li W., Savinov A.Y., Rozanov D.V., Golubkov V.S., Hedayat H., Postnova T.I., Golubkova N.V., Linli Y., Krajewski S., Strongin A.Y. Matrix metalloproteinase-26 is associated with estrogen-dependent malignancies and targets α1-antitrypsin Serpin. Cancer Res. 2004, 64:8657-8665.
33. Lucas R., Holmgren L., Garcia I., Jimenez B., Mandriota S.J., Borlat F., Sim B.K., Wu Z., Grau G.E., Shing Y., Soff G.A., Bouck N., Pepper M.S. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 1998, 92:4730-4741.
34. Määtä M., Soini Y., Liakka A., Autio-Harmainen H. Localisation of MT1-MMP, TIMP-1, TIMP-2, and TIMP-3 messenger RNA in normal, hyperplastic, and neoplastic endometrium. Enhanced expression by endometrial adenocarcinomas is associated with low differentiation. Am. J. Clin. Pathol. 2000, 114:402-411.
35. Matias-Guiu X., Catasus L., Bussaglia E., Lagarda H., Garcia A., Pons C., Munoz J., Arguelles R., Machin P., Prat J. Molecular pathology of endometrial hyperplasia and carcinoma. Hum. Pathol. 2001, 32:569-577.
36. Mitselou A., Ioachim E., Kitsou E., Vougiouklakis T., Zagorianakou N., Makrydimas G., Stefanaki S., Agnantis N.J. Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium. In Vivo 2003, 17:469-477.
37. Mohsin S.K., Weiss H., Havighurst T., Clark G.M., Berardo M., Roanhle D., To T.V., Qian Z., Love R.R., Allred D.C. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod. Pathol. 2004, 17:1545-1554.
38. Mutter G.L. Histopathology of genetically defined endometrial precancers. Int. J. Gynecol. Pathol. 2000, 19:301-309.
39. Neis K.J., Brandner P., Ulrich-Winkelspecht K. The oestrogen receptor (ER) in normal and abnormal uterine tissue. Eur. J. Cancer 2000, 36:S27-36.
40. Nephew K.P., Choi C.M., Polek T.C. Expression of fos and jun proto-oncogenes in benign versus malignant human uterine tissue. Gynecol. Oncol. 2000, 76:388-396.
41. Nunobiki O., Taniguchi E., Ishii A. Significance of hormone receptor status and tumor vessels in normal, hyperplastic and neoplastic endometrium. Pathol. Int. 2003, 53:846-852.
42. Oren M., Damalas A., Gottlieb T., Michael D., Taplick J., Leal J.F., Maya R., Moas M., Seger R., Taya Y., Ben-Ze'Ev A. Regulation of p53: intricate loops and delicate balances. Ann. N. Y. Acad. Sci. 2002, 973:374-383.
43. Otsuki Y. Apoptosis in human endometrium: apoptotic detection methods and signaling. Med. Electron. Microsc. 2001, 34:166-173.
44. Pearce S.T., Jordan V.C. The biological role of estrogen receptors alpha and beta in cancer. Crit. Rev. Oncol. Hematol. 2004, 50:3-22.
45. Pozzi A., Moberg P.E., Miles L.A., Wagner S., Soloway P., Gardner H.A. Elevated matrix metalloproteinase and angiostation levels in integrin alpha 1 knockout mice cause reduced tumor vascularisation. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:2202-2207.
46. Puente X.S., Sanchez L.M., Overall C.M., Lopez-Otin C. Human and mouse proteases: a comparative genomic approach. Nat. Rev. Genet. 2003, 4:544-558.
47. Rogers P.A., Lederman F., Plunkett D., Affandi B. Bcl-2, Fas and caspase 3 expression in endometrium from levonorgestrel implant users with and without breakthrough bleeding. Hum. Reprod. 2000, 15(Suppl. 3):152-161.
48. Ronnett B.M., Zaino R.J., Ellenson L.H., Kurman R.J. Endometrial carcinoma. Blaustein's Pathology of the Female Genital Tract 2002, 501-559. Springer-Verlag, New York. 5th edn. R.J. Kurman (Ed.).
49. Rubin H. Complementary approaches to understanding the role of proteases and their natural inhibitors in neoplastic development: retrospect and prospect. Carcinogenesis 2003, 24:803-816.
50. Salvesen H.B., Iversen O.E., Akslen L.A. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J. Clin. Oncol. 1999, 17:1382-1390.
51. Shiozawa T., Li S., Nakayama K., Nikaido T., Fujii S. Relationship between the expression of cyclins/cyclin-dependent kinases and sex-steroid receptors/Ki67 in normal human endometrial glands and stroma during the menstrual cycle. Mol. Hum. Reprod. 1996, 2:745-752.
52. Song J., Rutherford T., Naftolin F., Brown S., Mor G. Hormonal regulation of apoptosis and the Fas and Fas ligand system in human endometrial cells. Mol. Hum. Reprod. 2002, 8:447-455.
53. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 2005, 87:287-297.
54. Uchikawa J., Shiozawa T., Shih H. Expression of steroid receptor coactivators and corepressors in human endometrial hyperplasia and carcinoma with relevance to steroid receptors and Ki-67 expression. Cancer 2003, 98:2207-2213.
55. Vaskivuo T.E., Stenbäck F., Tapanainen J.S. Apoptosis and apoptosis-related factors Bcl-2, Bax, tumor necrosis factor-alpha, and NF-kappaB in human endometrial hyperplasia and carcinoma. Cancer. 2002, 95:1463-1471.
56. Velasco G., Pendas A.M., Fueyo A., Knauper V., Murphy G., Lopez-Otin C. Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J. Biol. Chem. 1999, 274:4570-4576.
57. Yamashita H., Otsuki Y., Matsumoto K., Ueki K., Ueki M. Fas ligand, Fas antigen and Bcl-2 expression in human endometrium during the menstrual cycle. Mol. Hum. Reprod. 1999, 5:358-364.
58. Yokoyama Y., Takahashi Y., Morishita S., Hashimoto M., Niwa K., Tamaya T. Telomerase activity in the human endometrium throughout the menstrual cycle. Mol. Hum. Reprod. 1998, 4:173-177.
59. Zhang H.G., Wang J., Yang X., Hsu H.C., Mountz J.D. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 2004, 23:2009-2015.